References
Terbah R, Chapman B, Gow P, Sinclair M, Angus P, Testro A. The efficacy, safety, and tolerability of outpatient continuous terlipressin infusion in patients awaiting liver transplantation. J Gastroenterol Hepatol. 2019;34:105.
Vasudevan A, Ardalan Z, Gow P, Angus P, Testro A. Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome. Hepatology. 2016;64:316–318.
Chapman B, Gow P, Angus P, Sinclair M, Testro A. Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant. J Hepatol. 2018;68:S726.
Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531–537.
Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983–992.
Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830–835. https://doi.org/10.1007/S10620-007-9919-9.
Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579–1589.e1572.
European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
Late-Breaking Abstracts—Presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting™ 2019. Hepatology. 2019;70:1477a–1501a.
Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Terbah, R., Gow, P., Sinclair, M. et al. Terlipressin for Type 1 Hepatorenal Syndrome. Dig Dis Sci 65, 2454–2455 (2020). https://doi.org/10.1007/s10620-020-06370-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-020-06370-8